|1.||Zhao, Hao-Liang: 1 article (02/2012)|
|2.||Li, Hui-Yu: 1 article (02/2012)|
|3.||He, Jie-Feng: 1 article (02/2012)|
|4.||Zhang, Jie: 1 article (02/2012)|
|5.||Mahadevan, D: 1 article (07/2008)|
|6.||Qi, W: 1 article (07/2008)|
|7.||Beeck, S: 1 article (07/2008)|
|8.||Stejskal, A: 1 article (07/2008)|
|9.||Goldman, A: 1 article (07/2008)|
|10.||Cooke, L: 1 article (07/2008)|
07/10/2008 - "Further, NSC348884 synergized doxorubicin cytotoxicity on cancer cell viability. "
07/10/2008 - "NSC348884 inhibited cell proliferation at an IC(50) of 1.7-4.0 muM in distinct cancer cell lines and disrupted NPM oligomer formation by native polyacrylamide gel electrophoresis assay. "
07/10/2008 - "NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells."
07/10/2008 - "Treatment of several different cancer cell types with NSC348884 upregulated p53 (increased Ser15 phosphorylation) and induced apoptosis in a dose-dependent manner that correlated with apoptotic markers: H2AX phosphorylation, poly(ADP-ribose) polymerase cleavage and Annexin V labeling. "
|2.||Hepatocellular Carcinoma (Hepatoma)
02/01/2012 - "To investigate the effect of NSC348884, a nucleophosmin small molecular inhibitor, on the growth of hepatocellular carcinoma cell line HepG2 and its underlying mechanism. "
02/01/2012 - "[Inhibitory effect of NSC348884, a small molecular inhibitor of nucleophosmin, on the growth of hepatocellular carcinoma cell line hepG2]."
|3.||Poly(ADP-ribose) Polymerases (Poly ADP Ribose Polymerase)